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Clozapine, by virtue of its absence of extrapyramidal side effects and greater efficacy, revolutionized the treatment of schizophrenia,
although the mechanisms underlying this exceptional activity remain controversial. Combining an unbiased cheminformatics and physical
screening approach, we evaluated clozapine’s activity at 42350 distinct molecular targets. Clozapine, and the closely related atypical
antipsychotic drug olanzapine, interacted potently with a unique spectrum of molecular targets. This distinct pattern, which was not
shared with the typical antipsychotic drug haloperidol, suggested that the serotonergic neuronal system was a key determinant of
clozapine’s actions. To test this hypothesis, we used pet1/ mice, which are deficient in serotonergic presynaptic markers. We
discovered that the antipsychotic-like properties of the atypical antipsychotic drugs clozapine and olanzapine were abolished in a
pharmacological model that mimics NMDA-receptor hypofunction in pet1/ mice, whereas haloperidol’s efficacy was unaffected. These
results show that clozapine’s ability to normalize NMDA-receptor hypofunction, which is characteristic of schizophrenia, depends on an
intact presynaptic serotonergic neuronal system.
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Schizophrenia, a devastating illness affecting nearly 1% of
the world’s population, appears to be a genetically
heterogeneous disorder with no single major risk allele
(Purcell et al, 2009; Shi et al, 2009; Stefansson et al, 2009;
Stefansson et al, 2008). This extreme genetic heterogeneity
will make it difficult, if not impossible, to develop
new medications that specifically target the presumably
dysregulated pathways. Despite the polygenic nature of
the illness, however, the symptoms of schizophrenia can
be reduced, to various degrees of efficacy, by antipsychotic
medications (Lieberman et al, 2005). Of the various
medications currently available to treat schizophrenia,
clozapine is uniquely effective (Kane et al, 1988).
Indeed, clozapineFa drug discovered 450 years ago
(Hippius, 1999)Fhas long been known to effectively treat
schizophrenia without associated extrapyramidal symptoms
(EPS) (Angst et al, 1971). Clozapine has also been
demonstrated to be uniquely effective in reducing suicid-
ality (Meltzer et al, 2003; Meltzer and Okayli, 1995).
Clozapine has a number of serious side effects, including
a nearly 1% risk of fatal agranulocytosis (Senn et al,
1977), limiting its use to treatment-resistant or treatment-
intolerant patients. The discovery of clozapine’s
characteristic ability to treat schizophrenia without indu-
cing EPS led to the development of the so-called ‘atypical’
antipsychotic drugs, which are now among the most
widely prescribed neuropsychiatric medications (Lieberman
et al, 2005).
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For many years, it has been appreciated that clozapine
and related atypical antipsychotics have extraordinarily
robust pharmacological profiles, with potent interactions at
a large number of mainly postsynaptically localized
biogenic amine receptors, including several serotonin
(Meltzer et al, 1989; Peroutka et al, 1981; Roth et al, 1992;
Roth et al, 1994), dopamine (Creese et al, 1976; Van Tol
et al, 1991), adrenergic (Enna et al, 1976), and muscarinic
(Bolden et al, 1992; Miller and Hiley, 1974) G-protein-
coupled receptors (GPCRs) (Roth et al, 2004). It is currently
unknown, and the subject of considerable controversy, which,
if any, of these pharmacological properties are essential for
either the unique spectrum of efficacy or the unusual side-
effect profile of clozapine. One aspect of their actions that has
recently become clear, however, is the observation that only
clozapine and the closely related atypical antipsychotic drugs
are effective in genetic and pharmacological models that
mimic the NMDA-receptor hypofunction of schizophrenia
(Abbas et al, 2009; Bakshi et al, 1994; Belforte et al, 2010;
Mohn et al, 1999) Without a clearer understanding of the
molecular and neuronal substrates responsible for these
actions, it will remain difficult, if not impossible, to develop
new antipsychotic drugs with either improved efficacies or
fewer side effects (Conn and Roth, 2008).
To discover the molecular and neuronal determinants of
clozapine’s actions, we utilized our unbiased chemical,
biological, and cheminformatic approaches to deconstruct
clozapine’s molecular and cellular actions (Armbruster and
Roth, 2005; Keiser et al, 2007; Keiser et al, 2009). We
discovered that clozapine and the related atypical anti-
psychotic drug olanzapine, but not haloperidol, displayed a
unique spectrum of activity at selected molecular targets.
This pattern of activity suggested to us that the serotonin
neuronal phenotype was an essential mediator of cloza-
pine’s actions. The ETS-domain transcription factor pet1
has recently emerged as a key determinant of the
serotonergic phenotype (Hendricks et al, 1999; Hendricks
et al, 2003; Jensen et al, 2008) of neurons, and pet1/ mice
almost completely lack the presynaptic component of the
serotonergic phenotype, including tryptophan hydroxylase
2 (Tph2), the serotonin transporter (SERT), the vesicular
monoamine transporter 2, and aromatic amino acid
decorboxylase in dorsal raphe neurons of adult KO mice.
These mice express only 20% of the adult level of 5-HT
(Hendricks et al, 2003). We discovered that genetically
induced deletion of the presynaptic component of the
serotonergic neuronal system selectively abolished the
ability of clozapine to normalize NMDA-receptor hypofunc-
tion in mouse pharmacological models of schizophrenia.
Importantly, genetic deletion of the main postsynaptic
receptor implicated in clozapine’s actions (HTR2A) did not
abolish clozapine’s therapeutic actions. These results
demonstrate an unexpectedly essential role for the pre-




A detailed description of how the pet1/ mice were
generated is provided elsewhere (Hendricks et al, 2003).
All experiments were approved by the institutional animal
care and use committee at the University of North Carolina,
Chapel Hill. Mice were housed under standard condi-
tionsF12 h light/dark cycle and food and water ad libitum.
Radioligand Binding Assays
For saturation binding assays, brain regions were rapidly
microdissected, frozen on dry ice, and then stored at
80 1C. A Tissue TearorTM (BioSpec Products) was used to
homogenize tissue (15 s, 15 000 r.p.m.) in ice-cold standard
binding buffer (SBBF50 mM Tris-HCl, pH 7.4; 10 mM
MgCl2; 0.1 mM EDTA). Homogenized tissue was centrifuged
for 20 min at 27 000 g (4 1C); crude membrane pellets were
collected and washed two more times in a total of 10 ml of
SBB. After the last wash, the membrane pellet was either
used immediately for binding, or stored at 80 1C until use.
Saturation binding assays were performed with the homo-
genized brain tissue and [3H]-ketanserin (5-HT2A; cortex)
or [3H]-WAY100635 (5-HT1A, cortex, midbrain, and hippo-
campus), and then incubated in SBB for 1.5 h as detailed
(Abbas et al, 2009). Nonspecific binding was determined by
incubating the reactions with 10 mM ritanserin (5-HT2A) or
10 mM buspirone (5-HT1A). Reactions were harvested by
vacuum filtration through glass filters (3 ice-cold 50 mM
Tris, pH 7.4; pH 6.9 at room temperature) and measured by
liquid scintillation using a Perkin-Elmer Tri-Carb 2800TR
scintillation counter. Nonlinear saturation analysis was
done using Graphpad Prism 4.01 to obtain Bmax values,
and Bradford protein assays were performed in order to




chloride) or vehicle was injected intraperitoneally (i.p.)
with light restraint to minimize stress effects, and mice were
killed 15 min later by cervical dislocation. Microdissection
was performed on ice as quickly as possible. For detection
of pERK1/2, tissue was homogenized in 300 ml of ice-cold
SBB plus protease and phosphatase inhibitor cocktails
(Roche Diagnostics, Complete, no. 11697498001; PhosSTOP,
no. 04906845001) and 5% glycerol, and centrifuged for
10 min at 20–25 000 g and 4 1C. Then, 25–30 mg of protein
from the supernatant was used to measure phospho- and
total ERK1/2 using 10% SDS-PAGE followed by immuno-
blotting. The following antibodies were used for western
blots in a 1 : 1000 dilution: rabbit polyclonal anti-
p-ERK1/2 antibody (9101L, Cell Signaling), and rabbit
polyclonal anti-ERK1/2 antibody (9102L, Cell Signaling).
For 5-HT2A receptor immunoblotting, frontal cortex crude
membrane preparations were resuspended in cold lysis
buffer (50 mM Tris-Cl, pH 7.4; 150 mM NaCl, 10% glycerol,
1% NP-40, 0.5% Na-deoxycholate, 0.5% CHAPS, plus
protease inhibitor cocktail (Roche Diagnostics) and in-
cubated on ice for 1 h. Detergent-soluble proteins were
collected after 20 min of centrifugation at 4 1C and 12 500 g,
and 500 mg (1.0 mg/ml) of protein was incubated with
25–30 ml (packed volume) of wheat germ agglutinin (WGA)-
conjugated agarose beads (Vector Technology) for a
minimum of 2 h at 4 1C on a rotary mixer. After three
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washes with 500 ml of lysis buffer, WGA-bound proteins
were eluted with 40 ml of 1 SDS-sample buffer, and whole
eluates were resolved by SDS-PAGE. Rabbit polyclonal anti-
5-HT2A receptor antibody (Neuromics, Edina, MN) was
used in a 1 : 500 dilution for 12 h at 4 1C for measurement of
5-HT2A receptor protein. We have previously verified the
specificity of the anti-5-HT2A receptor antibody using
5-HT2A WT and KO mice cortex tissue by immunoblotting
(Magalhaes et al, 2010)
Head-Twitch Response
As previously detailed (Abbas et al, 2009), mice were
injected i.p. with 0.5–5.0 mg/kg of DOI. Head twitches were
counted simultaneously by two observers (live, not on
recordings), one of whom was blinded to the genotype, and
recorded in 5-min bins for a total period of 30 min
immediately after injection.
Whole-Cell Recording in CA1 Pyramidal and Dorsal
Raphe Neurons
Adult pet1/ and pet1 + / + littermate mice were decapi-
tated, and their heads placed into a beaker containing ice-
cold oxygenated artificial cerebrospinal fluid (aCSF: (in
mM) sucrose 248, KCl 3.0, NaH2PO4 1.25, MgSO4 2.0, CaCl2
2.5, dextrose 10, and NaHCO3 26) for approximately 10 min.
Following this, the brain was removed, 200 mm vibratome
slices of the hippocampus or the midbrain were made and
placed in a holding chamber in a water bath (36 1C) for 1 h,
and then maintained at room temperature until used. Single
slices were placed in a recording chamber (Warner
Instruments, Hamden, CT), and continuously perfused
with aCSF (NaCl 124 mM replaced sucrose) at 2 ml/min at
32 1C maintained by an in-line solution heater (SH-27B,
Warner Instruments). Neurons were visualized using a
Nikon E600 (Optical Apparatus, Ardmore, PA) upright
microscope fitted with a  60 water-immersion objective,
differential interference contrast (DIC) optics, and an
infrared filter (IR). Recording pipettes were fashioned on
a P-97 micropipette puller (Sutter Instruments, Novato, CA)
using borosilicate glass capillary tubing (1.2 mm OD,
0.69 mm ID; Warner Instruments). The electrolyte for
recording cellular characteristics was (in mM): K gluconate
130, NaCl 5, MgCl2 1, Naphosphocreatinine 10, EGTA 0.02,
HEPES 10, MgATP 2, Na2GTP 0.5, and 0.1% Biocytin, pH
7.3. A visualized pyramidal cell in the CA1 subfield of the
dorsal hippocampus or a raphe neuron from the ventro-
medial subfield of the dorsal raphe was approached with the
electrode, a giga O seal established, and the cell membrane
ruptured to obtain a whole-cell recording using a multi-
clamp 700B amplifier (Axon Instruments, Foster City, CA).
Once the whole cell configuration was obtained, cell
characteristics were recorded using current clamp techniques.
The cellular characteristics were measured as previously
described (Beck et al, 2004). Following the collection of cell
characteristics, the pyramidal cell was returned to voltage
clamp mode at 60 mV. After a stable baseline was
established, 5-carboxyamidotryptamine (5-CT), a 5-HT1A
agonist, to a final concentration of 100 nM was added to the
aCSF, and the change in current was measured. Once a
steady-state response was established, the drug was removed
from the aCSF and only one cell was recorded per slice. The
access resistance and the input resistance were continuously
monitored throughout the recording period to assure quality
of the recordings. Recordings were abandoned if the access
resistance was more than four times the resistance of the
electrode, or if the input resistance changed by 415%. For
the dorsal raphe neurons, current clamp recordings were
obtained of the hyperpolarization induced by activation of the
5-HT1A receptor by addition of 5-CT (100 nM) to the
perfusion buffer. Unpaired t-tests were used to test for
significance using the statistical package Prism.
Immunohistochemistry
Adult mice were anesthetized and transcardially perfused
with 40 ml of phosphate-buffered saline (PBS), pH 7.4,
followed by 4% paraformaldehyde (PFA) in PBS, pH 7.4.
The brains were collected, postfixed overnight at 4 1C in 4%
PFA, followed by dehydration in a 30% sucrose (w/v)
solution in PBS overnight at 4 1C. Brain sections (30 mm
coronal sections) were permeabilized for 1 h with 0.4%
Triton X-100 in PBS, and were blocked for 2 h at room
temperature in PBS containing 3% bovine serum albumin,
1% normal goat serum, and 0.4% Triton X-100. The slides
were incubated with rabbit polyclonal anti-5-HT2A antibody
(1 : 250, Neuromics) in blocking buffer for 48 h at 4 1C,
followed by addition of anti-MAP2 mouse monoclonal
antibody (1 : 5000, Sigma), and further incubated overnight
at 4 1C. Slides were washed five times with PBS containing
0.4% Triton X-100; after that, goat anti-rabbit AlexaFluor-
488 and goat anti-mouse AlexaFluor-594 antisera (1 : 250,
Invitrogen, Eugene, OR) and Hoechst 3342 (0.5 mg/ml) were
applied to slides for 1 h at room temperature. Fluorescent
images were collected on a Nikon 80i Research Upright
Microscope (Nikon, Tokyo, Japan) equipped with Surveyor
Software with TurboScan (Objective Imaging, Kansasville,
WI). Tiled images were collected with a Qimaging Retiga-
EXi camera (Qimaging, Surrey, BC, Canada). Separate
images were collected for the 5-HT2A receptor, nucleus
(Hoechst), and MAP2 using either a  10 or  20 objective;
these images were taken at 16-bit resolution (ie, 11 000 by
15 000 pixels). The relative distribution of the 5-HT2A
receptor was quantified using ImageJ* software (NIH). Raw
images were corrected by subtracting the average intensity
value of the background. Twelve regions of interest (ROIs),
200 by 200 pixels, were randomly selected for layer V and
peripheral layers, the mean intensity was then measured for
each ROI, and these were averaged for each brain section. The
Hoechst and MAP2 staining were used as reference images.
Brain slice immunohistochemistry for biocytin and
tryptophan hydroxylase was conducted to determine
whether the neurons recorded from the pet + / + mice
contained 5-HT as previously described (Beck et al, 2004).
Slices from the pet1/ mice were also processed to detect
expression of the lacZ marker of 5-HT precursor neurons as
previously described (Scott et al, 2005), but using chicken
anti-b-galactosidase (1 : 1000, Abcam) and FITC-conjugated
goat anti-chicken (1 : 250, Abcam) antibodies.
Prepulse Inhibition of Acoustic Startle
All prepulse inhibition (PPI) experiments were performed
at the Mouse Behavioral Phenotyping Laboratory Core
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Facility in the Neurodevelopmental Disorders Research
Center of UNC using the SR-Lab equipment (San Diego
Instruments) as previously described (Abbas et al, 2009).
Briefly, mice were placed in a small Plexiglas cylinder
housed within a large sound-proofed chamber (San Diego
Instruments). Each session consisted of a 5-min habituation
period followed by 74 trials of 3 typesF(1) no stimulation,
(2) 120 dB acoustic stimulus (AS50), and (3) four different
prepulse stimuli ranging from 4 dB over background (PP68)
to 16 dB over background (PP78). PPI of acoustic startle was
measured in the presence of a 64-dB white-noise back-
ground. Mice were given three different types of trials. One
trial type consisted of a 40 ms 120 dB white-noise startle
stimulus. In the second, the startle stimulus was preceded
by a 20-ms prepulse stimulus that was 4, 8, 12, or 16 dB
above the white-noise background. In the third trial type, no
auditory startle stimulus was presented, but only prepulse
stimuli were presented, and these null trials served as
controls for background movements by the animals. During
testing, mice were acclimated to the apparatus for 5 min and
then given 74 test trials. In 30 of the trials, the 120 dB
stimulus was given alone (startle-only trials), whereas eight
additional trials served as null trials. For the remaining 36
trials, the prepulse stimulus preceded the startle stimulus by
100 ms. The behavioral responses were measured as the
peak startle response for each trial between 35 and 65 ms
after the onset of the startle stimulus. Inhibition of the
startle response was calculated for each intensity of prepulse
as the ratio of the prepulse trials to the startle-only trials
subtracted from 1 and expressed as a percentage inhibition
of response, that is, % PPI¼ [1–(prepulse trials/startle-only
trials)]*100. For pharmacological studies, pet1/ mice and
WT littermates were injected i.p. 30 min before PPI testing
with vehicle (saline), clozapine (0.5 or 1.0 mg/kg), and
olanzapine (0.5 mg/kg).
Locomotor and Stereotypic Activity
Locomotor activity was assessed in photocell-based activity
chambers under standardized environmental conditions,
using an AccuScan activity monitor (AccuScan Instruments,
Columbus, OH) with a 25.8 25.8 cm Plexiglas chamber
and a beam spacing of 1.52 cm as described (Abbas et al,
2009). Mice were injected i.p. with vehicle, haloperidol
(0.1 mg/kg), and clozapine (0.5 or 1.0 mg/kg) 30 min before
PCP (7.0 mg/kg), followed by placement in the activity
chambers. Activity data were collected for each mouse over
60 min, beginning when the mouse was first placed in the
testing chamber. Horizontal activity was measured as the
total distance covered in centimeters as the total of all
vectored X-Y coordinate changes. Stereotypy data were also
collected in this automated fashion and calculated by these
software packages based on contiguous breaks of the same
single beam or a set of beams. Data are presented as total
stereotypy counts, that is, number of repetitive beam breaks
during 60 min of activity monitoring.
Ligand Sets for SEA
We extracted ligand sets from databases that annotate
molecules by therapeutic or biological category (Keiser
et al, 2009). For instance, the 2006.1 MDL Drug Data Report
(MDDR) contains 518 molecules annotated as a1 adrenergic
receptor blockers, which we grouped into a single ‘a1
adrenergic blocker’ set. Three chemical databases provided
these ligand sets: the ChEMBL 2009 (available from EMBL-
EBI, http://www.ebi.ac.uk/chembldb), the World of Mole-
cular Bioactivity (WOMBAT) 2006.2 (Olah et al, 2004;
Oprea et al, 2007), and the MDDR 2006.1 (MDL, now
provided by Symyx) databases. For the ChEMBL and
WOMBAT data sets, we organized ligands by their affinities,
representing each protein target by three sets at 1 and 10 mM
cutoffs (as well as an additional 100 mM cutoff for
WOMBAT).
Similarity Ensemble Approach (SEA)
Clozapine, olanzapine, and haloperidol were computation-
ally screened via SEA against a panel of 3725 protein targets.
Each target was represented solely by its set of known
ligands. We used both the 1024-bit folded ECFP4 (Hert et al,
2008) and 2048-bit daylight (James et al, 1992) fingerprints
for SEA, as separate screens, and accepted the highest-
scoring predictions arising from either fingerprint. Because
of the small size of the query data set (three drugs), all SEA
predictions are reported here by P-values instead of by
E-values (Keiser et al, 2009).
Estimates of Number of Targets Screened
We extracted 3725 targets for the cheminformatics screen
from three databases: MDDR (246 targets), ChEMBL (2010
targets), and WOMBAT (1469 targets). However, there was
appreciable target overlap across databases; we estimate
that only 2250 of these targets are unique. To do so, we
extracted accession numbers and UniProt IDs for each
target and merged redundant targets via a synonym lookup
table using UniProtKB/SwissProt and UniProtKB/TrEMBL
database downloads (from http://www.uniprot.org, accessed
27 January 2010). We found 511 targets in common between
ChEMBL and WOMBAT, leaving 1499 targets only found in
ChEMBL and 536 targets only found in WOMBAT. Of the
536 WOMBAT-only targets, 296 did not have an accession
number or UniProt ID; we excluded these from our counts
to arrive at the lower-bounds estimate of 2250 unique
cheminformatics targets. We determined by manual inspec-
tion that 162 of the 307 targets from the physical screen
overlapped with the 2250-target cheminformatics screen.
This yielded a final estimate of 2395 unique targets screened
(Supplementary Table 3).
Kinase Profiling and Checkpoint Kinase 2 Assay
We profiled clozapine (10 mM) activity on a set of 20
different kinases using Caliper Profiler Pro kinase assays
and Labchip EZ reader according to the manufacturer’s
instruction (Caliper Life Sciences, Hopkinton, MA). The
CHK2 activity assay was carried out in opaque 96-well
plates using Omnia Kinase Assay Kit (Invitrogen,
KNZ1031). The assay was set up in triplicate in a final
reaction volume of 20 ml per well containing 10 mM of
peptide substrate, 1 mM DTT, and varying concentrations of
test drug or water to measure maximal kinase activity.
Thereafter, 18 mU of CHK2 enzyme protein (Invitrogen no.
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PV3367) was added to each well and the plate was loaded
immediately into a FlexStation II reader (Molecular
Diagnostics) at 30 1C, mixed for 5 s, and read (excitation
at 360 nm and emission at 485 nm) every 30 s for the next
60 min. Plateau readings at the 30 min point were processed
and analyzed to calculate IC50 of tested compounds using
GraphPad Prism 5.0.
Statistical Analysis
For quantitation of immunoblots, comparison of Bmax data,
and other two-group comparisons, two-tailed unpaired
t-tests were used to ascertain statistical significance. All
behavioral data were analyzed by two-way ANOVA followed
by Bonferroni post tests for comparing multiple groups.
Comparisons were considered significant if p-value was
o0.05.
RESULTS
Clozapine Interacts with a Defined Subset of Molecular
Targets
Because the molecular target(s) responsible for clozapine’s
actions remain controversial, we initially utilized an
unbiased physical screening approach in which clozapine
and selected typical and atypical antipsychotic drugs were
profiled against all known molecular targets implicated in
antipsychotic drug actions. The targets interrogated in-
cluded both validated antipsychotic drug targets (eg, D2, D3
dopamine; 5-HT2A serotonin) as well as most of the
currently investigated targets (eg, M1, M4 muscarinic;
mGluR2/3 metabotropic glutamate; nicotinic acetylcholine)
(Conn and Roth, 2008; Gray and Roth, 2007; Jensen et al,
2008). We then performed hierarchical clustering analysis
to identify atypical antipsychotic drugs that were most
similar to clozapine and typical antipsychotic drugs that
were most dissimilar. As shown in Figure 1a, olanzapine
was the most similar atypical antipsychotic drug to
clozapine, whereas haloperidol was the most dissimilar
typical antipsychotic drug. We then chose clozapine,
olanzapine, and haloperidol for further study.
The ‘druggable genome,’ of which the receptorome
(Armbruster and Roth, 2005), the kinome (Manning et al,
2002), enzymes, and other ‘druggable’ targets (Hopkins and
Groom, 2002) are part, is estimated to represent perhaps
2300 distinct molecular targets (Hopkins and Groom, 2002).
Although it is not currently technically feasible to obtain the
activity profile of clozapine at every conceivable druggable
target, we have been able to achieve satisfactory coverage of
these druggable targets falling into the GPCR, kinase,
transporter, ion channel, and enzyme classes. To investigate
whether there might be other likely targets, not available
among these readily screenable targets, we used our newly
validated computational SEA (Keiser et al, 2007; Keiser
et al, 2009) to screen all three drugs against a panel of
B2250 molecular targets, all of which have annotated
ligands. These calculations also allowed us to investigate the
similarities and differences in target association among the
three drugs; we were particularly interested to see whether
clozapine and olanzapine associated with similar targets,
and whether these differed substantially from the targets
with which SEA predicted haloperidol to associate (Supple-
mentary Table 1). SEA predicted only one new target for
clozapine, farnesyl protein transferase (PFTase, Supplemen-
tary Table 1). The SEA predictions suggested new targets for
olanzapine, such as the 5-HT3A serotonin receptor (HTR3A;
likelihood of random association, P-value, 1.09 1010), the
5-HT3B serotonin receptor (HatAR3B; P-value 1.18 108),
the H4 histamine receptor (HRH4; P-value 3.69 108),
and UDP-glucuronosyltransferase 1A4 (UGT1A4, P-value
1.63 1018; Supplementary Table 1). In each of these
cases, the olanzapine-predicted target is a known target of
clozapine that is neither predicted for nor known to interact
with haloperidol. However, upon inspection, each of these
targets is already reported to be a target for olanzapine in
KiDB, whereas UGT1A4 is known to directly glucuronidate
olanzapine (Linnet, 2002). Except for PFTase (P-value
2.46 105), none of the predicted targets differs greatly
from those that both drugs were already known to
modulate.
We next physically interrogated a large portion of the
druggable genome to determine if there could be additional
targets for clozapine that were not predicted by SEA.
Figure 1b shows the combined results obtained from our
queries of internally derived physical screening campaigns
from the NIMH-PDSP as well as the publicly available
physical screening campaigns extracted from the PubChem
database (see Supplementary Table 2 for the complete data
set) at 4300 target-based assays. As shown in Figure 1b and
Supplementary Table 2, clozapine and olanzapine differed
from haloperidol by virtue of their high-affinity interactions
with most of the 14 human serotonin GPCRs and relatively
lower affinity interactions with D2, D3, and D4 dopamine
receptors. Furthermore, Figure 2a shows the lack of activity
of clozapine at various protein kinases implicated in
psychotherapeutic drug actions (eg, GSK3b, Erk1, Erk2,
and Akt1) (Beaulieu et al, 2009; Beaulieu et al, 2008;
Beaulieu et al, 2005). In passing, we note that clozapine was
a moderately potent inhibitor of CHK2 (Figure 2b)Fa
kinase involved in cell cycle regulation (Matsuoka et al,
1998).
The Presynaptic Component of Serotonin Neurons Is
Essential for Clozapine’s Ability to Normalize the
NMDA-Receptor Hypofunction Characteristic of
Schizophrenia
The results of Figure 1 suggested to us that the most likely
locus of clozapine’s actions was engagement of the
serotonergic neuronal system. Because many serotonin
receptors are both pre- and post-synaptic with respect to
serotonin neurons, it was not clear whether the requirement
for serotonergic engagement would be pre- or post-
synaptic, although current hypotheses posit a selective
effect of clozapine on postsynaptic serotonin receptors (eg,
HTR2A, HTR2C, HTR6, and HTR7; Conn and Roth, 2008;
Roth et al, 2004). These hypotheses predict that deletion of
the presynaptic component of the serotonin neuronal
system would not affect clozapine’s therapeutic actions.
To test these hypotheses, we took advantage of the
observation that the ETS-domain transcription factor pet1
is essential for normal expression of the serotonergic
phenotype in neurons, and that its deletion greatly
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diminishes expression of presynaptic serotonergic markers
(Hendricks et al, 2003; Jensen et al, 2008; Scott et al, 2005).
For initial studies, we examined the ability of clozapine to
normalize the disruption of PPI induced by the noncompe-
titive NMDA-receptor antagonist phencyclidine (PCP). We
chose PCP because it is known to induce a psychotic state
that reliably mimics both the positive and negative
symptoms of schizophrenia in humans (Javitt and Zukin,
1991). Disrupted PPI is also well established and validated
as a measure of the impaired sensory-motor gating
characteristic of schizophrenia (Geyer and Braff, 1987;
Mansbach and Geyer, 1989). Importantly, atypical anti-
psychotic drugs like clozapine are unique in their
ability to normalize PCP-induced disruption of PPI (Bakshi
Figure 1 Mining the druggable genome identifies molecular targets for clozapine action. (a) Results from hierarchical clustering analysis of affinities of
approved typical and atypical antipsychotic drugs at molecular targets implicated in antipsychotic drug action (Gray and Roth, 2007; Roth et al, 2004). See
Supplementary Table 2 for complete data set. Arrow indicates location of node specifying clozapine and olanzapine. (b) Summary results from an
interrogation of clozapine, olanzapine, and haloperidol at 4300 distinct molecular targets (see Supplementary Table 2 for complete data set).
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et al, 1994). As is shown in Figure 3a, acute administration
of PCP induced a marked disruption of PPI in both pet1/
and pet1 + / + littermate control mice. Significantly,
clozapine normalized PCP-disrupted PPI in pet1 + / + but
not in pet1/ mice (Figure 3a). To determine if these
results were unique to clozapine, we tested olanzapine as
well, because it most closely mimics the polypharmacolo-
gical profile of clozapine. As shown in Figure 3b, olanzapine
normalized PCP-disrupted PPI in pet1 + / + but not in
pet1/ mice. These results indicate that genetic deletion
of pet1 abolishes the ability of both clozapine and
olanzapine to normalize NMDA-receptor hypofunctioning.
Therefore, the actions of clozapine and olanzapine depend
on the presynaptic component of the serotonergic neuronal
system. We also examined the ability of clozapine to
normalize the PCP-induced enhancement of locomotor
activity and stereotypy. As shown in Figures 3c and d and 4,
PCP induced a significant enhancement of locomotor
behavior and stereotypical movements, which were normal-
ized by clozapine in pet1 + / + (Figure 3c) but not in pet1/
(Figure 3d) mice. As an essential control, we show that the
typical antipsychotic haloperidol normalized locomotor
behavior and stereotypy in both pet1 + / + and pet1/ mice
(Figures 3e, f and 4a)Fa result predicted based on its
relatively selectively potent interaction with D2-family
dopamine receptors, in contrast to the profiles of clozapine
or olanzapine, which more preferentially target 5-HT
receptors.
Given these results, we wondered if genetic deletion of
5-HT2A serotonin receptors, which have been proposed to
mediate many of clozapine’s unique actions (Meltzer et al,
1989), might phenocopy pet1 deletion, at least with respect
to clozapine’s antipsychotic-like actions. Accordingly, we
examined the ability of clozapine to normalize PCP-induced
disruption of PPI in 5-HT2A
+ / + and 5-HT2A
/ mice. As shown
in Figure 4b, clozapine normalized PCP-induced PPI
disruption in both 5-HT2A
/ and WT littermate control
mice. We also noted that 5-HT2A
+ / + and 5-HT2A
/ mice were
generated on the 129S background strain and displayed a
diminished sensitivity to clozapine. We performed dose
response with clozapine (data not presented) in these mice,
and the data with the lowest effective doses of clozapine in
5-HT2A
/ and WT littermates are shown in Figure 4b. These
results indicate that postsynaptic 5-HT2A receptors are not
essential for mediating clozapine’s ability to normalize PCP-
induced disruption of sensory-motor gating in vivo.
Given these results, we wondered if one possible
explanation for the inability of clozapine to normalize
behavioral measures of NMDA-receptor hypofunction could
be that genetic disruption of pet1 has altered the cellular
expression and/or sensitivity of postsynaptic 5-HT2A
serotonin receptors. To address this possibility, we mea-
sured cortical 5-HT2A receptor protein levels via western
blot, 3H-ketanserin radioligand binding, and immunofluor-
escence analysis. We found equivalent amounts of 5-HT2A
receptor protein, radioligand binding (Figure 5a–c), and a
similar cellular and subcellular distribution of 5-HT2A
receptors in pet1 + / + and pet1/ mice (Figure 5d and e).
To determine if a change in postsynaptic 5-HT2A receptor
sensitivity was present in pet1/ mice, we evaluated DOI-
induced head-twitch and pERK responses in pet1 + / + and
pet1/ mice, as previously described (Abbas et al, 2009).
As can be seen in Figure 5f–h, DOI-induced responses were
augmented in pet1/ mice, as might be expected given the
loss of presynaptic 5-HT innervations seen in pet1/ mice.
We also determined the 5-HT2C expression level in
hippocampus, as clozapine has affinity for this receptor,
and found significantly increased 5-HT2C expression in
hippocampus of pet1/ mice in comparison with WT
littermate controls (Supplementary Figure 1). Furthermore,
the antipsychotic-like properties of M100907 (5-HT2A
selective antagonist) and MK212 (5-HT2C selective agonist)
for normalizing the PCP-induced disruption of PPI is
selectively blunted in pet1/ mice (Supplementary
Figures 2 and 3). These results indicate that the inability
of atypical antipsychotic drugs to normalize NMDA-
receptor hypofunction in pet1/ mice is not because of
5-HT2A or 5-HT2C postsynaptic receptor insensitivity.
Figure 2 Kinase profiling reveals activity of clozapine only at checkpoint
kinase 2 (ChK2). (a) Shown are results from a kinase profile performed with
a Caliper microfluidics-based screening platform (part no. 760373) that
comprises 20 different purified kinases. Clozapine (10 mM) was tested
against all the kinases shown above and data are presented as % inhibition
of kinase activity. (b) Dose-response studies with clozapine and the
nonspecific kinase inhibitor staurosporine at Chk2. Data represent
mean±error of N¼ 3 separate determinations. EC50 values determined
using GraphPad Prizm.
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It has also been suggested that clozapine-like drugs exert
their effects principally via direct (or indirect) activation of
5-HT1A serotonin receptors (Newman-Tancredi et al, 1998;
Rollema et al, 1997). It is conceivable, therefore, that a
diminution of 5-HT1A receptor number and/or sensitivity
could exist in mice with a genetic deletion of pet1. To
address this possibility, we quantified cortical 5-HT1A
receptors via 3H-WAY100635 radioligand binding and
found that pet1/ mice showed more (not less) 3H-
WAY100635 binding than pet1 + / + mice in the cortex and
hippocampus (Figure 6a). We also examined the electro-
physiological properties of 5-HT1A receptors in hippocam-
pal slices from pet1 + / + and pet1/ mice and found, as
would be expected from the binding data, a significantly
exaggerated response in pet1/ when compared with
pet + / + mice (Figure 6b and c). Taken together, these
results indicate that clozapine’s inability to rescue NMDA-
receptor hypofunctioning is not because of diminished
forebrain 5-HT1A receptor expression or activity.
Finally, and most critically, we interrogated the physio-
logical function of the presynaptic component of the
serotonin neuronal system to verify its relative ablation in
pet1/ mice. We first utilized the psychotomimetic agent
methylene-dioxy-methamphetamine (MDMA) that induces
locomotion via a presynaptic release of 5-HT. As shown in
Figure 7a and b, the locomotor effects of MDMA were
Figure 3 The presynaptic component of serotonin neuronal system is required for clozapine’s therapeutic actions in vivo. (a) Effect of clozapine
(C, 0.5 mg/kg or 1.0 mg/kg) on PCP (7.0 mg/kg)-induced disruption of prepulse inhibition (PPI) was measured. In pet1 + / + mice, clozapine pretreatment
completely normalized disruption of PPI by PCP at all prepulse levels, whereas it had no effect on pet1/ mice (N¼ 16/group). (b) Effect of olanzapine
(O, 0.5 mg/kg) on PCP (7.0 mg/kg)-induced disruption of PPI was measured. Similar to clozapine, olanzapine also did not exhibit any significant effect on PCP-
induced PPI deficit in pet1/ mice. (c, d) Pretreatment (30 min) with clozapine (0.5 mg/kg) significantly blocked PCP (7.0 mg/kg)-induced hyperactivity in
pet1 + / + mice, but had no significant effect on pet1/ mice (N¼ 14 per group). Data are expressed as mean total horizontal distance traveled in 5-min bins
over 60 min after PCP administration (±SEM). (e, f) Haloperidol (Hal, 0.1 mg/kg) significantly attenuated PCP-induced hyperactivity in both genotypes
(N¼ 12 per group). Data are expressed as mean total horizontal distance traveled over 60 min in 5-min bins after PCP administration (±SEM). *po0.05,
two-way ANOVA followed by Bonferroni post tests for multiple comparisons.
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abolished in pet1/ mice. We next tested the presynaptic
5-HT1A receptor-mediated response electrophysiologically
in midbrain raphe slices from pet1 + / + and pet1/ mice.
The magnitude of the 5-HT1A hyperpolarization recorded
from the pet1 knockout mice was significantly less, and 14
out of the 24 neurons recorded demonstrated no response at
all, as shown in Figure 7c and d. In contrast, the responses
recorded from the pet1 wild-type mice were normal in
magnitude (Figure 7c and d). These results confirm a
functional ablation of the presynaptic component of the
serotonergic neuronal system in pet1/ mice. Taken
together, these results demonstrate that an intact presynap-
tic component of the 5-HT neuronal system is essential for
clozapine’s actions.
DISCUSSION
In this paper, we identify the presynaptic component of the
serotonin neuronal system as an essential mediator of
atypical antipsychotic drug action in vivo. Although literally
thousands of studies have been published regarding
clozapine’s actions, the molecular substrates essential for
its unique effects remain intensely controversial. Indeed,
previous studies have demonstrated that clozapine and
related atypical antipsychotic drugs have preferentially high
affinity for postsynaptic 5-HT2A serotonin (Meltzer et al,
1989), D4 dopamine (Van Tol et al, 1991), muscarinic
acetylcholine (Miller and Hiley, 1974), as well as dozens of
other GPCRs (Roth et al, 2004). Indeed, each of these
Figure 4 5-HT2A receptor is not essential for clozapine’s antipsychotic drug actions. (a) Pretreatment (30 min) with clozapine (0.5 mg/kg) significantly
blocked PCP (7.0 mg/kg)-induced stereotypy in pet1 + / + mice, but had no significant effect on pet1/ mice (N¼ 8 per group). However, haloperidol
(0.1 mg/kg) significantly attenuated PCP-induced stereotypy in both group of mice. Data are expressed as mean total stereotypy counts in 60 min after PCP
administration (±SEM). *po0.01, two-way ANOVA followed by Bonferroni post test for multiple comparisons. NS, not significant. (b) Clozapine
normalizes the PCP induced PPI deficit in 5-HT2A KO mice. Effect of clozapine on PCP (7.0 mg/kg)-induced disruption of prepulse inhibition (PPI) was
measured. Clozapine pretreatment (30 min) completely normalized disruption of PPI by PCP in both WT and KO mice (N¼ 8 per group). *po0.01, two-
way ANOVA followed by Bonferroni post test for multiple comparisons.
Figure 5 Postsynaptic supersensitivity of 5-HT2A receptors following deletion of pet1. (a) Immunoblot of WGA immunoprecipitates from cortex
membrane lysate of two representative pet-1/ and pet1+ / + littermate pairs. The same blots were stripped and probed for transferrin receptor as loading
controls. (b) Densitometry of immunoblots of WGA IP from five pairs of WT and pet1/ mice. (c) Bmax estimates were obtained by performing [
3H]-
ketanserin saturation binding on DLFC membrane homogenates. Data are presented as mean±SEM (N¼ 5 per group). (d) 5-HT2A receptor (green, top
and bottom panels) and MAP2 (red) immunochemistry in coronal sections of a pet1/ and pet + / + littermate pair. Middle panel is overlay of 5-HT2A
(green), MAP2 (red), and Hoechst (blue) immunostaining to compare the distribution of 5-HT2A receptors between dendrites and cell bodies. (e) Estimates
of 5-HT2A receptor abundance by immunofluorescence in layer V and in peripheral layers. 12 regions of interest (ROIs), 200 by 200 pixels, were randomly
selected for both layer V and the peripheral layers. The mean intensity was then measured for each ROI and these were averaged for each brain section
(N¼ 3 per genotype). (f) 5-HT2A-mediated signaling is potentiated in pet1/ mice. Representative immunoblot of DOI (5.0 mg/kg, i.p. 15 min)-induced
pERK1/2 and total ERK1/2 (as loading control) in microdissected cortical lysates. (g) Densitometry of DOI-induced pERK1/2 immunoblots; data are
expressed as % vehicle (veh), N¼ 5 to 6 per group, *po0.05, one-way ANOVA followed by Neuman–Keuls post hoc analysis for multiple comparisons. (h)
DOI (0.5–5.0 mg/kg)-induced head twitches were counted as measure of hallucinogenic activity; data are expressed as mean±SEM (N¼ 6–8 per group,
*po0.05, **po0.01; unpaired t-test).
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individual molecular targets to which clozapine binds with
high affinity has been subsequently exploited for drug
discovery purposes. Drugs that have been developed that
attempt to mimic clozapine’s actions by selectively targeting
these ‘clozapine receptors’ have all failed to be approved as
efficacious treatments of schizophrenia. This spectacular
drug discovery failure prompted us to re-examine the
molecular and neuronal substrates responsible for cloza-
pine’s actions in vivo.
To comprehensively and in an unbiased fashion identify
all the potential site(s) of action of clozapine, we initially
screened a representative sample of known typical and
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atypical antipsychotic drugs against a panel of known
molecular targets implicated in antipsychotic drug
actions. Hierarchical clustering revealed that clozapine
and olanzapine were most similar to each other among
approved atypical antipsychotic drugs, and were very
distinct from haloperidol. We then evaluated these three
drugs against 4300 distinct molecular targets to gain
satisfactory physical screening coverage of the ‘druggable
genome’ (Hopkins and Groom, 2002). We discovered that
clozapine and olanzapine differed from haloperidol mainly
by virtue of high affinities for nearly all known 5-HT
receptors. In passing, we noted that clozapine and
olanzapine were weak inhibitors of Chk2Fa checkpoint
kinaseFalthough the potencies of clozapine and olanza-
pine for Chk2 (B10 mM) are probably too low to be of
therapeutic relevance. One unique class of druggable targets
represented in our screen are the orphan GPCRs. Despite
screening 26 of these orphans, we have failed to identify
unique clozapine targets among them (data not shown).
Efforts are ongoing to screen all 160 + orphan GPCRs as
potential clozapine targets (WK Kroeze and BL Roth,
unpublished).
To cast an even wider net, we also employed a new and
unbiased computational method, the SEA, to identify
possible targets for these three drugs beyond the panel of
targets explicitly screened (Keiser et al, 2007; Keiser et al,
2009). SEA predictions predominantly recapitulated the
known targets of these drugs, and even where new and
previously uncharacterized targets were suggested for
olanzapine, these had already been characterized for
clozapine. Indeed, clozapine and olanzapine often shared
predicted targets by SEAFprimarily aminergic
GPCRsFwith which haloperidol was not predicted to
associate. Combining the 307 targets interrogated
from the physical screening campaign and the 2250
targets from the SEA screen, we have interrogated over
2350 targets by a combination of these two methods. Taken
together, these results indicate that the three drugs
evaluated interact mainly with known biogenic amine
receptors, and that the probability is low that any additional
druggable targets exist that could account for the unique
actions of clozapine.
Given the preferentially high affinity of clozapine and
olanzapine for most known 5-HT receptors, we postulated
that the serotonergic neuronal system is required for
clozapine’s action. Indeed, for decades, it has been
suggested, without confirmatory studies using knockout
mice, that 5-HT and its receptors are key mediators of
clozapine’s actions (Fink et al, 1984; Carlsson et al, 1999).
Here, we took advantage of the observation that genetic
deletion of pet1 results in a generalized loss of 5-HT and
the presynaptic component of the serotonin neuronal
system (Hendricks et al, 2003). This diminution of brain
serotonin led to an enhancement in 5-HT2A, 5-HT2C, and
5-HT1A responses. However, despite this apparent
postsynaptic supersensitivity, we found that deletion of
pet1 abolished clozapine’s efficacy. Importantly, we also
found that genetic deletion of 5-HT2A receptorsFhereto-
fore considered the main target implicated in clozapine’s
actionsFonly marginally attenuated clozapine’s antipsy-
chotic-like actions. Instead, these present findings implicate
the presynaptic component of the 5-HT neuronal system as
being essential for clozapine’s unique actions.
Figure 6 Upregulation and supersensitization of postsynaptic 5-HT1A
receptors in pet1/. (a) Comparison of 5-HT1A expression (Bmax
estimates) in cortex, midbrain, and hippocampus. Bmax values were
obtained by [3H]-WAY100635 saturation binding, and data are presented
as mean±SEM (N¼ 5 to 6 per genotype). *po0.05, unpaired t-test. (b, c)
5-CT-induced changes in whole-cell current in CA1 pyramidal neurons. (a)
Representative chart recordings of current elicited by bath application of
5-CT. All cells were recorded in voltage clamp mode with cells held at
60 mV; length of line above each chart depicts the amount of time the
drug was in chamber. (b) Graphical presentation of whole-cell current
index are presented from 12 cells per group derived from 6 mice per
genotype. (*po0.05, unpaired t-test.)
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Implications of These Findings for Psychiatric Drug
Discovery
Although there is little debate regarding clozapine’s unique
efficacy in treating schizophrenia, the molecular and
neuronal determinant(s) of clozapine’s actions remain
highly controversial. Some groups have proposed that
clozapine is uniquely efficacious because of a combination
of relatively low D2 receptor affinity (and associated fast
dissociation rate) and/or high D4 dopamine receptor
affinity (Kapur and Seeman, 2001; Seeman et al, 1997).
This approach has led to the successful development of
drugs like amisulpride that are relatively selective D2/D3
dopamine receptor antagonists (Schoemaker et al, 1997).
Others have suggested that clozapine via its principal
metabolite N-desmethylclozapine potentiates NMDA-receptor
function by virtue of M1 muscarinic receptor agonism
(Sur et al, 2003; Wittmann et al, 2005). This hypothesis has
led to a new crop of muscarinic subtype-selective allosteric
potentiators currently being developed (Conn and Roth, 2008;
Gray and Roth, 2007). Furthermore, it has also been shown
that clozapine can potentiate NMDA activity by directly
binding to glycine B site (Bressan et al, 2005; Javitt et al, 2005;
Schwieler et al, 2008), thus contributing to its unique clinical
efficacy. Clearly, however, the PCP-induced PPI disruption
and hyperlocomoter response in mice do not model all aspects
of schizophrenia and, therefore, other potential actions of
clozapine were not addressed here.
Others, most prominently Meltzer and colleagues (Nash
et al, 1988), who discovered that clozapine and related
atypical antipsychotic drugs were characterized by relatively
higher affinities for postsynaptic 5-HT2A serotonin recep-
tors (HTR2A) when compared with D2 receptors, suggested
that a balanced antagonism of 5-HT2A/D2 was required.
This hypothesis led to the successful development of many
currently prescribed atypical antipsychotic drugs, although
none of them recapitulates the unique efficacy of clozapine
(Lieberman et al, 2005). Meltzer and colleagues (Li et al,
2009) have also reported a requirement for cortical
postsynaptic 5-HT1A receptors in mediating certain actions
of clozapine and related atypical antipsychotic drugs. Based
on the relatively high affinity of clozapine for various 5-HT
receptors, a number of attempts have been made to develop
clozapine-like atypical antipsychotic drugs that function as
inverse agonists for various postsynaptic 5-HT2A, 5-HT2C,
5-HT6, and 5-HT7 receptors (Gray and Roth, 2007),
although, to date, these efforts have not yielded approved
atypical antipsychotic drugs.
Many other molecular target-based approaches for
developing atypical antipsychotic drugs are currently
underway. These include targeting various components of
the glutamate synapse (eg, mGluR2/3 allosteric potentiators,
mGluR5 potentiators, GlyT1 glycine transporter inhibitors,
and AMPA receptor potentiators), nicotinic acetylcholine
subtype-selective agents, phosphodiesterase 10A inhibitors,
NK3-neurokinin receptor antagonists, and others (Conn
Figure 7 Serotonin neurons are silent in pet1/ mice. (a, b) MDMA-induced locomotor response is abolished in pet1/ mice. pet1/ and pet1 + / +
littermate controls were injected with 5 mg/kg (a) or 10 mg/kg (b) MDMA after a 30-min acclimatization and then locomotor activity was measured for the
next 90 min. *po0.05, two-way ANOVA followed by Bonferroni correction for multiple comparisons. (c, d) 5-CT-induced changes in membrane potential
recorded from the ventromedial subfield of the dorsal raphe. (c) Representative chart recording (in current clamp mode) of a neuron from pet1 + / + mice
showing the hyperpolarization induced by 5-CT (100 nM) bath application. (d) The graph summarizes the findings from all of the recorded cells identified as
5-HT containing in the pet1 + / + mice or as 5-HT precursor neurons by b-galactosidase staining in the slices from pet1/ mice (N¼ 24 per genotype,
*po0.001, unpaired t-test).
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and Roth, 2008; Gray and Roth, 2007; Karam et al, 2010).
At present, it is unknown which, if any, of the above
mechanistically designed (or single-target-based) ap-
proaches to treat schizophrenia require an intact presynap-
tic serotonergic neuronal system, although we are actively
engaged in evaluating many of these drugs in pet1/ mice
(PN Yadav et al, unpublished).
By way of contrast, our results indicate that the
presynaptic component of the serotonin neuronal system
is a key determinant of clozapine’s antipsychotic-like
actions in mice in vivo. Therefore, a key feature for new
antipsychotics would be a requirement for activity at the
presynaptic component of the serotonergic neuronal system
while simultaneously targeting various postsynaptic recep-
tors to yield maximum efficacy. Clearly, designing such
drugs with a focused serotonergic action, while minimizing
side effects, will be the challenge for the next revolution in
treating schizophrenia.
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